SCHEMBL6084339

SCHEMBL6084339

COc1cc(OC)c(CC(=O)Nc2cccc(-c3n[nH]cc3-c3nc4cc5ccccc5cc4o3)c2)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RY14 Q15391 9/20 0.51
USP2 O75604 3/20 0.49
ALDH1A1 P00352 3/20 0.49
HPGD P15428 3/20 0.49
RAB9A P51151 3/20 0.49
TSHR P16473 2/20 0.49
HSD17B10 Q99714 2/20 0.49
NPC1 O15118 2/20 0.49
GAA P10253 2/20 0.49
KDM4E B2RXH2 2/20 0.49
POLB P06746 1/20 0.49
MAPK1 P28482 1/20 0.49
TP53 P04637 1/20 0.48
KDR P35968 4/20 0.47
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6083942 0.86 P2RY14 (0.54) P2RY14USP2ALDH1A1HPGDHSD17B10
SCHEMBL6086054 0.84 P2RY14 (0.63) P2RY14TP53KDRMAPT
SCHEMBL6222058 0.83 HSD17B10 (0.47) P2RY14USP2ALDH1A1HPGDRAB9A
SCHEMBL6085449 0.83 TP53 (0.59) ALDH1A1HPGDRAB9AHSD17B10NPC1
SCHEMBL6085102 0.82 MAPT (0.54) USP2ALDH1A1HPGDRAB9ATSHR
SCHEMBL6084095 0.81 HSD17B10 (0.48) P2RY14USP2ALDH1A1HPGDRAB9A
SCHEMBL6084732 0.81 P2RY14 (0.54) P2RY14ALDH1A1HPGDRAB9ANPC1
SCHEMBL6086347 0.80 P2RY14 (0.51) P2RY14USP2ALDH1A1HPGDRAB9A
SCHEMBL6086508 0.79 POLB (0.57) P2RY14USP2ALDH1A1HPGDRAB9A
SCHEMBL6085686 0.79 TP53 (0.53) P2RY14ALDH1A1HPGDRAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 P2RY14 1920/4885USP2 2427/4885ALDH1A1 3486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.